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Occupational Carcinogens:
ELF MFs
Siemiatycki et al. (2004) published a list of
occupational carcinogens based largely on the
evaluations published by the International
Agency for Research on Cancer (IARC), aug-
mented with additional information on the
extent of workplace exposure. They consid-
ered 28 agents as definite human occupa-
tional carcinogens (IARC group 1), 27 agents
as probable occupational carcinogens (group
2A), and 113 agents as possible occupational
carcinogens (group 2B). However, missing
from their list of occupational carcinogens is
magnetic fields (MFs) at extremely low fre-
quencies (ELF; 3–3000-Hz), which were
classified as group 2B by IARC (2002).
IARC’s final conclusion (IARC 2002) is
as follows: 
Overall, extremely low frequency magnetic fields
were evaluated as possibly carcinogenic to
humans (IIB), based on the statistical association
of higher level residential ELF magnetic fields
and increased risk for childhood leukaemia.
Thus, although the evaluation is based on
epidemiologic studies of childhood leukemia,
the classification applies to all human expo-
sure to ELF MFs, and thus also to occupa-
tional exposure. This interpretation has
been discussed and confirmed with an
IARC representative on their ELF MF
panel (Cardis E, personal communication).
Because enough workers are exposed to
ELF MFs to clearly meet the criteria for
occupational exposures set by Siemiatycki
et al. (2004), we are surprised that they did
not include it in their list of possible occu-
pational carcinogens.
Other groups and agencies have applied
IARC’s criteria to the evaluation of ELF MF
carcinogenicity. The National Institute of
Environmental Health Sciences working
group (NIEHS 1998) evaluated the research
in that era and classified ELF EMFs (electric
and magnetic fields) as possibly carcinogenic
(group 2B); this classification was based on
the occurrence of chronic lymphocytic
leukemia (CLL) associated with occupa-
tional exposure. The California Department
of Health Services also evaluated the cancer
risks of EMF in 2002, and their reviewers
classified it as at least group 2B, including
childhood leukemia and adult brain cancer
(Neutra et al. 2002). 
Since the IARC evaluation, several rele-
vant studies have been published—both
in vitro and in vivo work, as well as epi-
demiologic studies, including the following
examples. Tynes et al. (2003) reported an
association between exposure to calculated
residential MFs and cutaneous malignant
melanoma. In a cohort including all female
workers, Weiderpass et al. (2003) found an
association between exposure to electro-
magnetic fields and stomach and pancreatic
cancer; Villeneuve et al. (2002) found that
occupational MF exposure increased the
risk of glioblastoma multiforme; Håkansson
et al. (2002) investigated cancer incidence
in resistance welding workers exposed to
high levels of MF and found that men in
the very high exposure group showed an
increased incidence of tumors of the kid-
ney, pituitary gland, biliary passages, and
liver; an exposure–response relationship was
indicated for these cancer sites. Women in
the very high exposure group showed an
increased incidence of astrocytoma I–IV,
with a clear exposure–response pattern. 
Ivancsits et al. (2002, 2003a, 2003b)
have shown that human lymphocytes
exposed to ELF MFs can generate DNA
single and double strand breaks from a flux
density as low as 35 µT and with a strong
correlation between both the intensity and
duration of the MF exposure. 
The IARC evaluation (IARC 2002)
ruled out a probable carcinogen classification
(group 2A) because the expert panel found
the animal studies were “inadequate evidence
of carcinogenicity.” This judgment was due
to many conflicting results in the repetition
of long-term animal experiments. In particu-
lar, Löscher and Mevissen (1995) reported
that MF exposure to Sprague-Dawley (SD)
rats after 7,12-dimethylbenz[a]anthracene
(DMBA) initiation increased breast tumors
in the exposed animals at 50 µT compared
with the control group (see also Thun-
Battersby et al. 1999). However, in a similar
study Anderson et al. (1999) found no evi-
dence for a cocarcinogenic or tumor-pro-
moting effect of MF exposure, but the study
used different substrains of SD rats than used
in the original study. Anderson et al. (2000)
stated that “the U.S. rats were more suscepti-
ble to DMBA than the European rats”; diet
and DMBA were from different sources, and
there were differences in environmental con-
ditions and in MF exposure metrics.
Fedrowitz et al. (2004) compared two sub-
strains of SD outbred rats; MF exposure sig-
nificantly increased mammary tumor
development and growth in one of the
strains of rats but not in the other. These
data suggest that genetic background may
play a pivotal role in effects of MF exposure;
this which might explain the difficulties in
replicating the original animal studies of
breast tumor promotion. 
According to the criteria used by
Siemiatycki et al. (2004), a complete list
of occupational agents classified as possi-
ble human carcinogens would include
ELF MFs.
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ELF MFs: Straif et al. Respond
Mild et al. suggest that we should have
included magnetic fields at extremely low
frequencies (ELF MFs) in our listing of
occupational carcinogens (Siemiatycki et al.
2004). We acknowledge that ELF MFs have
been classified as “possibly carcinogenic to
humans” (Group 2B) by the Monographs
Programme of the International Agency for
Research on Cancer (IARC 2002) and that
there is significant occupational exposure,
thereby meeting our operational criterion
for inclusion as a possible occupational car-
cinogen. However, the nature of the evi-
dence that led to the IARC classification
complicates the designation of ELF MFs as
an occupational carcinogen.
For our article (Siemiatycki et al. 2004),
we drew on the evaluations of the IARC
Monographs Programme. Each evaluation
was based on data that were available at the
time of the deliberations of the working
group. We supplemented the evaluation by
adding information on major occupational
exposure circumstances and on the cancer
sites affected. For some carcinogens, notably
those evaluated recently, such information
was explicitly mentioned in the published
monograph, but for others it was based on
our expert judgment.
For ELF MFs, the IARC evaluation of
“possibly carcinogenic” was founded on a
determination that there was limited evi-
dence of carcinogenicity in humans based
on its effects on childhood leukemia and
“inadequate evidence” in experimental ani-
mals (IARC 2002). In contrast with an
earlier evaluation [National Institute of
Environmental Health Sciences (NIEHS)
1998], the IARC Working Group considered
that studies conducted among adults, at work
or elsewhere, did not provide consistent
enough and strong enough evidence to sup-
port an evaluation of carcinogenicity. There is
no clear-cut way to classify an exposure that
has only been demonstrated to be carcino-
genic (albeit group 2B) in children, but also
occurs among workers. Although we decided
not to include ELF MFs in our tables of
occupational carcinogens (Siemiatycki et al.
2004), we could have done so with a footnote
to explain that the evidence supporting that
evaluation was based on children.
Mild et al. also discuss the evidence on
the carcinogenic effects of ELF MFs that has
arisen since 2002. Although we agree that
some of these studies may substantially con-
tribute to an evaluation of the carcinogenic
effects of ELF MFs, it was not in the scope
of our work to evaluate new information and
update the evaluations on all of the agents
reviewed. The World Health Organization
(WHO) will be holding a meeting of an
Environmental Health Criteria Task Group
in October 2005; this task group will evalu-
ate the health effects of ELF MFs (including
cancer and noncancer outcomes). We antici-
pate that they will review the recent evidence
in conjunction with the evaluation of the
2002  IARC Monograph. The WHO
Environmental Health Criteria document on
ELF MFs should be published shortly after
this meeting.
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The NAS Perchlorate Review:
Second-Guessing the Experts
The Committee to Assess the Health
Implications of Perchlorate Ingestion
[National Academy of Sciences (NAS)]
released its final report [National Research
Council (NRC) 2005] in January 2005,
recommending a reference dose (RfD) for
perchlorate of 0.0007 mg/kg-day. In a com-
mentary published online on 25 May 2005,
Ginsberg and Rice (2005) criticized the ade-
quacy of the NAS committee’s scientific
deliberations, mischaracterizing the studies
reviewed by the committee and second-
guessing its conclusions. Ginsberg and Rice
(2005) implied that the U.S. Environmental
Protections Agency’s (EPA’s) previous draft
RfD of 0.00003 mg/kg-day (U. S. EPA
2002)—and by inference the Massachusetts
perchlorate risk assessment [Massachusetts
Department of Environmental Protection
(Mass DEP) 2004] that mirrored the U.S.
EPA’s approach and which Ginsberg and
Rice peer reviewed—is more scientifically
defensible. 
The NAS committee was composed of
15 leading physicians and scientists with
combined range of expertise to evaluate
every scientific aspect of the perchlorate
database and of the U.S. EPA’s assessment
of that database. The makeup of this com-
mittee and its credentials are available on
the NAS website (NAS 2004). The NAS
committee studied and deliberated for more
than 15 months before issuing its report.
Those deliberations included three public
meetings during which it accepted verbal
and/or written comments from the U.S.
EPA, other government agencies, industry,
states, environmental groups, and attorneys.
After careful study and consideration of the
scientific studies that formed the basis for
the U.S. EPA’s 2002 draft RfD as well as
the 2004 Massachusetts risk assessment
(Mass DEP 2004), the NAS committee
considered 
several of the animal studies … to be flawed in
their design and execution. Conclusions based on
those studies, particularly the neurodevelopmental
studies, were not supported by the results of the
studies.
Although Ginsberg and Rice (2005)
implied that the NAS committee should
have considered the threshold for measurable
iodine uptake inhibition “adverse” and that
the NAS inadvertently left out the “A” in
NOAEL (no observed adverse effect level),
the committee decisively stated that “inhibi-
tion of iodide uptake by the thyroid clearly is
not an adverse effect.” The committee care-
fully considered the issue of a NOEL (no
observed effect level) and a NOAEL. Based
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perchlorate long term, the NAS established
the NOAEL as 0.4 mg/kg-day (57 times
higher than its identified NOEL). 
Ginsberg and Rice (2005) further
expressed concerns regarding perchlorate in
breast milk and the subsequent possibility of
decreased breast milk iodine, citing Kirk
et al. (2005) and Gibbs (2004). Kirk et al.
(2005) reported perchlorate and iodide levels
in breast milk samples and noted that “if we
take all the available data, there is no mean-
ingful correlation between the perchlorate
and iodide levels in breast milk.” The study
from Chile that Ginsberg and Rice refer to as
Gibbs (2004) is now published as Tellez
et al. (2005). The study found that iodine
nutrition of pregnant women in Chile is very
similar to that in the United States. Tellez
et al. (2005) found no maternal or neonatal
perchlorate-related thyroid effects or
decreases in breast milk iodine with perchlo-
rate doses spanning the 0.0007–0.007
mg/kg-day range.
Ginsberg and Rice (2005) argued that
perchlorate database deficiencies require an
additional uncertainty factor of 3–10 because
of key data gaps, citing breast milk concerns
and the extrapolation from a 14-day expo-
sure study to chronic exposure. The NAS
committee (NRC 2005) considered this and
concluded that 
if inhibition of iodide uptake by the thyroid is
duration-dependent, the effect should decrease
rather than increase with time, because compen-
sation would increase the activity of the sodium-
iodide symporter and therefore increase iodide
transport into the thyroid.
Evidence has subsequently shown this to be
the case (Braverman et al. 2005).
The California EPA perchlorate risk
assessment (California EPA 2004) relied on
the same studies as the NRC report (NRC
2005). The “point of departure” was based
on iodine uptake inhibition by Greer et al.
(2002), and a total uncertainty factor of 10
was applied to account for interindividual
variability. After reviewing the NRC report
(NRC 2005), the California EPA elected
not to change its risk assessment or public
health goal (California EPA 2005).
In summary, the concerns presented by
Ginsberg and Rice (2005) have already been
addressed thoroughly by experts on perchlo-
rate and thyroid toxicology and were found
to be unsubstantiated. The NAS committee
and other experts came to this conclusion
based on a comprehensive review of the sci-
ence in the field, not based entirely on an
individual study, which has been mischarac-
terized by Ginsberg and Rice.
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The NAS Perchlorate Review:
Adverse Effects?
Ginsberg and Rice (2005) argued that the
reference dose for perchlorate of 0.0007
mg/kg per day recommended by the National
Academy of Sciences (NAS) Committee to
Assess the Health Implications of Perchlorate
Ingestion is not adequately protective. As
members of the committee, we disagree.
Ginsberg and Rice (2005) based their
conclusion on three points. The first
involves the designation of the point of
departure as a NOEL (no observed effect
level) versus a LOAEL (lowest observed
adverse effect level). The committee chose as
its point of departure a dose of perchlorate
(0.007 mg/kg per day) that, when given for
14 days to seven normal subjects, did not
cause a statistically significant decrease in the
group mean thyroid iodide uptake (Greer
et al. 2002). Accordingly, the committee
considered it a NOEL. Ginsberg and Rice
(2005) focused on the fact that only seven
subjects were given that dose; they seem to
say that attention should be paid only to the
results in those subjects in whom there was a
decrease in thyroid iodide uptake and that
the results in those in whom there was no
decrease or an increase should be ignored.
They considered the dose to be a LOAEL
because of the decrease in uptake in those
few subjects. It is important to note that a
statistically significant decrease of, for exam-
ple, 5% or even 10% would not be biologi-
cally important and, more important, would
not be sustained. For example, in another
study (Braverman et al. 2004), administra-
tion of 0.04 mg/kg per day to normal sub-
jects for 6 months had no effect on thyroid
iodide uptake when measured at 3 and
6 months, and no effect on serum thyroid
hormone or thyrotropin concentrations
measured monthly. [Inspection of Figure 5A
in Greer et al. (2002) suggests that this dose
would inhibit thyroid iodide uptake by
about 25% if measured at 2 weeks.] 
The second issue involves database
uncertainty. In clinical studies, perchlorate
has been administered prospectively to
68 normal subjects for 2 weeks to 6 months.
In one study (Brabant et al. 1992), a dose of
9.2 mg/kg per day for 4 weeks had no effect
on thyroid function. In occupational studies,
doses as high as 0.5 mg/kg per day had no
effect on thyroid hormone or thyrotropin
production in workers. In epidemiologic
studies, there were no abnormalities in
growth or thyroid function in children
exposed life-long to 100–120 µg perchlorate
per liter of drinking water, or in pregnant
women and newborn infants similarly
exposed. Given the choice of a nonadverse
effect (inhibition of iodide uptake by the
thyroid) as the point of departure and the
multiple studies in which doses of perchlo-
rate much higher than 0.007 mg/kg per day
had no effect on any aspect of thyroid func-
tion, the committee did not apply a database
uncertainty factor. 
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that inhibition of thyroid iodide uptake is
adverse. That conclusion assumes that any
acute inhibition would be sustained, so thyroid
hormone production would decrease. That is
not the case. There is remarkable compensation
for even substantial reductions in thyroid
iodide uptake—and thyroid hormone produc-
tion. As noted above, subjects given
0.04 mg/kg per day for 6 months and
9.2 mg/kg per day for 4 weeks—doses that cer-
tainly would inhibit thyroid iodide uptake for a
few weeks—had no decrease in serum thyroid
hormone or increase in serum thyrotropin con-
centrations (the hallmark of even mild hypo-
thyroidism). Short-term inhibition of thyroid
iodide uptake is not an adverse effect; it has no
adverse consequences because there is rapid
compensation mediated by several independent
processes. One of these processes is up-regula-
tion of the thyroid sodium-iodide transport sys-
tem, as a result of intrathyroidal iodide
deficiency. The second, should there be even a
very small decrease in thyroid hormone pro-
duction, is an increase in thyrotropin secretion,
resulting in overall stimulation of the thyroid
gland. Analyses of the effects of any substance
on thyroid function must take these compen-
satory processes into account, particularly the
fact that the effect of any substance that inhibits
thyroid function will diminish with time. Only
if all of these mechanisms fail will there be
hypothyroidism, the first adverse effect in the
continuum of effects resulting from perchlorate
ingestion. If there is no inhibition of iodide
uptake to begin with, there will be no other
changes in thyroid function at any time.
We believe that the committee’s recom-
mended reference dose of 0.0007 mg/kg
per day provides a wide margin of safety for
all subjects of all ages.
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The NAS Perchlorate Review:
Is the RfD Acceptable?
Risk assessors should always carefully evalu-
ate whether a given reference dose (RfD) is
the most appropriate choice for assessing
risk. In the case of perchlorate, Ginsberg
and Rice (2005) suggested that the RfD
proposed by the National Research Council
(NRC) is inappropriate because the NRC
did not thoroughly evaluate the underlying
science. However, we suggest that the NRC
RfD is inappropriate because of the NRC’s
“unconventional” approach.
In contrast to Ginsberg and Rice (2005),
we applaud the insightful and conclusive dis-
cussion of the science of perchlorate and the
thyroid by the NRC (2005). The NRC con-
cluded that human studies are the most rele-
vant for risk assessment, and that the thyroid
has a remarkable ability to compensate for
iodine deficiency, so that hypothyroidism
would be the first observed adverse effect. By
definition, this is perchlorate’s critical effect
(Faustman and Omenn 2001), although
U.S. Environmental Protection Agency
(EPA) methods allow for the use of a known
and immediate precursor (the choice of
immediate precursor is based on practice of
using the highest no observed adverse effect
level (NOAEL) of the critical effect and is
codified in several places (e.g., Barnes and
Dourson 1988, p. 473). The NRC also con-
cluded that in healthy adults the perchlorate
dose required to cause hypothyroidism
would be > 0.4 mg/kg-day.
In risk assessment parlance, this dose
would be a NOAEL of the critical effect. The
practice of risk assessment allows us to draw
conclusions about public health in the absence
of observable data and in the presence of scien-
tific uncertainty. The traditional practice of
developing RfD, a dose–response part of risk
assessment (Barnes and Dourson 1988),
would suggest two possible approaches to
developing an RfD from the perchlorate data.
The first would be to use the NOAEL of the
critical effect from an adult population and
apply uncertainty factors to account for sensi-
tive populations and for lack of precision in
defining a NOAEL. The second approach
would be to use the NOAEL of an immedi-
ate precursor effect in a sensitive population
and apply appropriate uncertainty factors.
Using the first approach with the NRC
NOAEL, the RfD would lie in the range of
0.04–0.004 mg/kg-day depending on the
choice of uncertainty factor. Using the sec-
ond approach, a NOAEL of 0.005 mg/kg-
day (Gibbs et al. 2004) can be identified
from thyroid hormone and goiter data in a
sensitive population. The RfD based on this
approach would lie near the value of
0.002 mg/kg-day proposed by Strawson
et al. (2004). 
In contrast, the approach the NRC actu-
ally used was a nonstandard approach for
developing an RfD based on the inhibition
of iodine uptake, a distant precursor to the
critical effect. This nonstandard approach
yields a safe dose, but it is not an RfD, by
definition, because, according to the NRC’s
own scheme, it is not based on the critical
effect or its known and immediate precursor. 
We continue to advocate that the best
risk assessment approach for perchlorate is to
use data collected from sensitive populations
such as children and, in particular, the pub-
lished and ongoing work in Chile. This is
consistent with the NRC’s conclusion that
the data from Chile could be considered in
the evaluation of the U.S. experience with
perchlorate in drinking water (NRC 2005).
Specifically, the Chilean experience (Crump
et al. 2000; Tellez et al. 2005) can be used to
help frame the public debate in the United
States, which suggests perchlorate water stan-
dards as low as 1 ppb. In Chile, perchlorate
water concentrations of 100–120 ppb do not
result in an exposure that would inhibit
iodine uptake inhibition in adults. In fact,
these concentrations have not caused any
adverse effects in pregnant women, neonates,
or older children exposed chronically.
Following traditional RfD methods and
using data from a sensitive human popula-
tion results in an RfD that can be used with
high confidence in the United States.
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the best use of toxicity data for risk values.
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The NAS Perchlorate Review:
Ginsberg et al. Respond
We would like to respond to the com-
ments from several members of the NAS
perchlorate panel (Johnston et al.) and
from two other groups (Gibbs et al.,
Strawson et al.). These letters were in
response to our commentary published in
EHP (Ginsberg and Rice 2005). The let-
ters take an opposing viewpoint but do not
invalidate our main assertions that a) the
low dose reported in the Greer et al. study
(Greer et al. 2002) does in fact demon-
strate a majority of subjects with the per-
chlorate-induced effect; b) there is the
potential for greater perchlorate vulnera-
bility in pregnant women and newborns
than in the general population; and
c) inhibition of iodide uptake is a key step
in the perchlorate toxicodynamic pathway,
with moderate levels of uptake inhibition
potentially sufficient to produce adverse
effects in sensitive subgroups. 
The low dose reported by Greer et al.
(2002) was termed a no observable effect
level (NOEL) by the National Research
Council (NRC 2005). We disagreed with
this view in our commentary because four
of seven individuals at this dose showed
the characteristic perchlorate-induced
suppression of iodine uptake. Johnston
et al. claim that we ignored the nonre-
sponders when we described the low dose
in the Greer study (Greer et al. 2002) as
an effect level. We did not disregard these
subjects, but we pointed out that they
segregate out as a subgroup who appear
to be less sensitive to the perchlorate
effect and have low baseline values. We
further pointed out that, because of the
small sample size (n = 7), there is very lit-
tle statistical power to detect an effect at
Greer et al.’s low dose (0.007 mg/kg/day)
given the variability in response. Rather
than simply relying on a weak test of sig-
nificance, our closer inspection of the
data indicated that the majority of the
low-dose subjects were responders. When
the results are organized categorically into
responders and nonresponders, it is evi-
dent that the low dose is part of the dose–
response continuum with no evidence of
a threshold: 0.5 mg/kg/day, 9 responders
out of 9 subjects; 0.1 mg/kg/day, 10
responders out of 10 subjects; 0.02
mg/kg/day, 6 responders out of 10 sub-
jects; and 0.007 mg/kg/day, 4 responders
out of 7 subjects. The lack of statistical
significance should not be used as
grounds for disqualifying what appears to
be a biologically significant response. 
Hydrogen sulfide provides a good
example for illustrating biologic versus
statistical significance. In a key study,
Jappinen et al. (1990) found that an
inhaled dose of hydrogen sulfide did not
cause a statistically significant effect on
airway parameters in a group of 10 sub-
jects with asthma. However, when these
data were used by the Agency for Toxic
Substances and Disease Registry (ATSDR)
to set a public health benchmark (the
acute minimum risk level), the fact that 2
of the 10 asthmatics were responders was
sufficient for this dose to be considered a
critical effect level (ATSDR 1999). The
perchlorate low-dose responders should
not be ignored, just as the hydrogen sul-
fide low-dose responders were not
ignored. 
Although the NRC considered Greer
et al.’s (2002) low dose a NOEL, like us,
the U.S. Environmental Protection
Agency (EPA) draft assessment (U.S. EPA
2002) and a risk assessment by the
Massachusetts Department of Environ-
mental Protection (Mass DEP 2004) con-
sidered this dose to be a LOAEL (lowest
observed adverse effect level). The
California EPA conducted a benchmark
dose analysis on the data published by
Greer et al. (2002), finding
0.0037 mg/kg/day (approximately 2-fold
below Greer et al.’s low dose) the critical
point of departure for standard setting
(California EPA 2004). 
Strawson et al. make the argument that
the critical adverse effect of perchlorate is
hypothyroidism. It is important to under-
stand that clinical hypothyroidism is not
the critical end point for derivation of the
perchlorate RfD. Subclinical hypo-
thyroidism in pregnant women can result
in adverse nervous system effects in off-
spring (Zoeller et al. 2002), including
decreased IQ (Haddow et al. 1999).
Perchlorate’s inhibition of iodine uptake
increases the risk for hypothyroidism,
which even if subclinical, may still be asso-
ciated with neurodevelopmental effects. 
The rebuttal letters (Gibbs et al.,
Johnston et al., and Strawson et al.) con-
sider inhibition of iodine uptake a nonad-
verse effect because it is only temporary
and because compensatory homeostatic
mechanisms would not allow actual
declines in thyroid hormone to occur.
They cite an abstract by Braverman et al.
(2004) to demonstrate that the perchlorate
effects seen by Greer et al. (2002) disappear
upon longer-term (6 month) exposure. As
we pointed out in our commentary
(Ginsberg and Rice 2005), the study by
Braverman et al. (2004) has not been pub-
lished or peer reviewed and involves small
numbers of subjects. It is unclear whether
there was sufficient statistical power to see
the perchlorate effect. Since the publica-
tion of our commentary we became aware
of a different study by this same group
(Braverman et al. 2005). Gibbs et al. also
mentioned this study. In contrast to their
abstract (Braverman et al. 2004),
Braverman et al. (2005) show iodine
uptake inhibition in relatively young male
Caucasian workers who had a median per-
chlorate exposure period of 5.9 years. The
dose response for these long-term perchlo-
rate workers was similar to that shown for
subjects exposed to perchlorate for 2 weeks
(Greer et al. 2002). This suggests that,
contrary to the NRC report (NRC 2005)
and Braverman et al. (2004), perchlorate
does not lose its potency to inhibit iodide
uptake under conditions of long-term
exposure. 
The fact that the workers in the study
by Braverman et al. (2005) did not have
indications of thyroid deficiency suggests
that healthy workers can compensate for
this type of biochemical impairment.
This is likely due to several factors,
including sufficient iodide and hormone
reserves in these workers. However, it is
uncertain that perchlorate-induced
impairment of iodine uptake would be
compensated for in all members of the
population. In particular, a substantial
percentage of the general public has low
iodine intake [Centers for Disease
Control and Prevention (CDC) 2000;
Hollowell et al. 1998], pregnant women
can be at greater risk for iodine deficiency
(Azizi et al. 2003), and the neonate
appears to have minimal stores of thyroid
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et al. 1999). In addition, the data of
Braverman et al. (2005) suggest up-regu-
lation of the iodide symporter in these
workers, a protective mechanism that
may not exist in the fetus or neonate.
Infants have added susceptibility because
perchlorate is excreted into breast milk
and appears to inhibit iodine secretion
into breast milk (Kirk et al. 2005).
On this last point, the letter by Gibbs
et al. casts doubt on the relationship
between perchlorate and iodine levels in
breast milk by quoting from Kirk et al.
(2005): “If we take all the available data,
there is no meaningful correlation between
the perchlorate and iodide levels in breast
milk.” This is a case of selective quoting, as
the very next sentence states, “On the other
hand, for breast milk that contained
≥ 10 µg/L perchlorate, the iodide concen-
tration expressed in milk is linearly related
to the reciprocal of perchlorate concentra-
tion.” Although we would agree that the
findings of Kirk et al. (2005) need to be
further explored, Gibbs et al.’s dismissal
of these findings—on the basis of an out-
of-context quote—is misleading. 
Strawson et al. claim in their letter that
the NRC used a nonstandard approach in
deriving the perchlorate RfD. Citing an
article by Barnes and Dourson (1988), they
state that there are two possible approaches
to developing an RfD: the use of a
NOAEL of a critical effect from an adult
population, or the use of the NOAEL of a
precursor effect in a sensitive population.
Barnes and Dourson (1988) did not dis-
cuss such a dichotomy of approaches, nor
did more recent U.S. EPA guidance (e.g.,
U.S. EPA 1991, 2002). In fact, IRIS (the
Intergrated Risk Information System; IRIS
2005) defines “critical effect” as “[T]he
first adverse effect, or its known precursor,
that occurs to the most sensitive species.”
There is no distinction in any of these doc-
uments made for critical end point being
chosen based on sensitive population, nor
is there discussion of “immediate precur-
sor” versus other precursors, a distinction
made by Strawson et al. Therefore, the
assertion that the NRC used a nonstandard
approach in using a precursor event in a
nonsensitive population (adults) is not sup-
ported in U.S. EPA guidance (U.S. EPA
1991, 2002).
Also at issue are the uncertainty factors
that need to be applied to the data of
Greer et al. (2002) to derive a health-pro-
tective RfD. The NRC risk assessment
included a total 10-fold uncertainty factor
(NRC 2005). This factor is expected to
cover a lot of ground: variability in toxico-
kinetics and toxicodynamics among
healthy adults, variability caused by low
iodine uptake, pregnancy, neonatal vulner-
abilities described above, and the data gaps
and temporal uncertainties described in
our commentary (Ginsberg and Rice
2005). Because of these factors, our scien-
tific judgment is that a 10-fold uncertainty
factor is insufficient, which is the same
judgment arrived at in the U.S. EPA draft
assessment (U.S. EPA 2002) and in the
Massachusetts risk assessment (Mass DEP
2004). 
The letters of Gibbs et al. and
Strawson et al. allude to the Chilean data
set (Crump et al. 2000; Tellez et al. 2005)
as documenting that early life stages are
not especially affected by relatively high
exposure to perchlorate in drinking water.
If this were the case, it would decrease the
level of uncertainty contained in the risk
assessment. However, in our commentary
(Ginsberg and Rice 2005), we pointed out
the limitations of the Chilean data. It
requires extrapolation from an iodine-
enriched population in Chile to the
United States, which has considerably less
iodine intake. Further, nearly 5% of
school-age children and 15% of women of
childbearing age in the United States have
low iodine intake (CDC 2000; Hollowell
et al. 1998) these individuals are likely not
well represented by the Chilean data set.
Crump et al. (2000) show an association
between high perchlorate in drinking
water and family history of thyroid disease.
The fact that this association did not
extend to altered thyroid status in the chil-
dren studied raises the possibility that
iodine supplementation efforts in recent
decades in Chile prevented the perchlorate
effect in current-day children (Crump
et al. 2000). This leaves open the question
of perchlorate-induced effects in children
in the United States whose iodine intake is
suboptimal. A follow-up study by Tellez
et al. (2005) reproduces some of the earlier
Chilean findings but shows that in spite of
very recent reductions in the iodide con-
tent of salt in Chile, iodine levels are still
approximately 2-fold higher there than in
the United States. The Chilean studies do
not remove the uncertainties present in the
perchlorate database. 
Our disagreement with the NAS per-
chlorate document (NRC 2005) and
with these letters centers around how a
no effect level is defined and how vulner-
able life stages are factored into a risk
assessment. These authors recommend
stretching the definition of NOEL to
include a dose level in which the major-
ity of the subjects demonstrate the per-
chlorate effect. Gibbs et al., Johnston
et al., and Strawson et al. also recom-
mend using studies of healthy adults and
a poorly matched Chilean population to
dismiss the adverse nature of perchlorate-
induced iodide uptake inhibition for vul-
nerable subgroups. As state risk assessors,
we strive to keep methods and judgment
consistent across all chemicals. Applying
that to perchlorate leads us to a different
analysis than what was presented by the
NAS and what is promoted in the letters
responding to our commentary (Ginsberg
and Rice 2005). 
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ERRATUM
In Figure 2D of Greer et al. [Environ
Health Perspect 110:927–937 (2002)],
there should have been seven subjects in
the 0.007 mg/kg-day group, but EHP
erroneously included an extra line (with-
out symbols), indicating a nonexistent
eighth subject. This error was reproduced
in the commentary of Ginsberg and Rice
[Environ Health Perspect 113:1117–1119
(2005)] and was included in their argu-
ment that there was an inhibitory effect
overall in that dose group.
EHP regrets the error.
D
40
35
30
25
20
15
10
5
0
BV
2
4
-
h
r
 
R
A
I
U
 
(
%
1
2
3
I
 
a
d
m
i
n
i
s
t
e
r
e
d
)
E14 P15
Figure 2D.The 24-hr thyroid radioiodine uptake
(RAIU) at the baseline visit (BV) and on exposure
day 14 (E14) and postexposure day 15 (P15) for each
subject in the 0.007-mg/kg-day dose group.